Sriram Ryali Acquires 17,360 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) CFO Sriram Ryali acquired 17,360 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was acquired at an average cost of $1.42 per share, with a total value of $24,651.20. Following the transaction, the chief financial officer now directly owns 17,360 shares of the company’s stock, valued at approximately $24,651.20. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Caribou Biosciences Stock Performance

Shares of NASDAQ:CRBU traded down $0.03 during trading on Thursday, hitting $1.31. The company’s stock had a trading volume of 1,625,759 shares, compared to its average volume of 1,531,784. The company has a market capitalization of $118.62 million, a PE ratio of -0.79 and a beta of 2.34. Caribou Biosciences, Inc. has a fifty-two week low of $1.30 and a fifty-two week high of $8.33. The stock’s 50-day moving average price is $1.79 and its two-hundred day moving average price is $1.99.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $3.37 million. On average, equities analysts predict that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. PFM Health Sciences LP lifted its position in shares of Caribou Biosciences by 5.5% during the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock worth $8,441,000 after purchasing an additional 223,299 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after buying an additional 536,162 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after acquiring an additional 124,782 shares in the last quarter. FMR LLC increased its holdings in shares of Caribou Biosciences by 7.4% in the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after acquiring an additional 109,606 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Caribou Biosciences during the 2nd quarter valued at approximately $2,432,000. 77.51% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Citigroup decreased their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Bank of America lowered their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.